Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Fibroscan® and Its Dedicated Probes Efficiency in Obese Patients

This study has been completed.
Information provided by:
Echosens Identifier:
First received: June 22, 2009
Last updated: November 15, 2010
Last verified: November 2010
The main objective of the study is to evaluate the diagnostic performance of the XL probe for estimating degree of liver fibrosis/cirrhosis in obese patients > 28 kg/m² with various liver diseases in patients with chronic liver disease scheduled for a liver biopsy.

Condition Intervention
Liver Fibrosis
Device: FibroScan M and XL probes

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Fibroscan® and Its Dedicated Probes Efficiency in Obese Patients

Resource links provided by NLM:

Further study details as provided by Echosens:

Primary Outcome Measures:
  • diagnosis accuracy for the assement of significant fibrosis and cirrhosis [ Time Frame: at enrollement ]

Estimated Enrollment: 300
Study Start Date: July 2009
Study Completion Date: September 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: FibroScan M and XL probes
    Each patient undergo two liver stiffness measurements with the FibroScan: once with the M probe and once with the XL probe

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient of at least 18 years of age
  • Patient able to give written informed consent form
  • Patient with a BMI superior or equal to 28kg/m²
  • Patient scheduled to have a liver biopsy within 1 month after the enrollment or with a liver biopsy performed within 6 months before the enrollment.
  • Patient for which abdominal ultrasound is technically possible

Exclusion Criteria:

  • Unable or unwilling to provide written informed consent
  • Confirmed diagnosis and/or history of malignancy, or other terminal disease
  • Patients with clinical ascites
  • Pregnant women
  • Patient with a BMI < 28 kg/m²
  • Patients with any active implantable medical device (such as pacemaker or defibrillator)
  • Transplanted patient and patient with heart disease
  • Refusal to undergo a liver biopsy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00926224

Canada, Alberta
Calgary University Hospital
Calgary, Alberta, Canada, T2N 4N
Canada, Ontario
London University Hospital
London, Ontario, Canada, N6A 5A5
Toronto Western General Hospital
Toronto, Ontario, Canada, M5T 2S8
Toronto Liver Centre
Toronto, Ontario, Canada, M6H 3M1
Canada, Quebec
Saint-Luc University
Montreal, Quebec, Canada, H2X 3J4
Sponsors and Collaborators
  More Information

Responsible Party: Celine Fournier, Echosens Identifier: NCT00926224     History of Changes
Other Study ID Numbers: M111
Study First Received: June 22, 2009
Last Updated: November 15, 2010

Keywords provided by Echosens:
Adult patients with chronic liver disease scheduled for a liver biopsy and a BMI superior or equal to 28 kg/m²

Additional relevant MeSH terms:
Liver Cirrhosis
Liver Diseases
Digestive System Diseases processed this record on May 23, 2017